Ironwood files Form 144 for Class A RSU sales
Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.
Rhea-AI Filing Summary
Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.
Each listed award was granted under the Issuer's 2019 Equity Incentive Plan or its amended and restated 2019 Equity Incentive Plan. The filing lists the securities and grant dates associated with the proposed sales.
Positive
- None.
Negative
- None.
Insights
Form 144 reports proposed resale of RSU-derived Class A shares with specific grant dates and counts.
The filing identifies restricted stock unit awards granted under the 2019 Equity Incentive Plan and its amended and restated form, listing discrete award amounts tied to 03/08/2022, 03/08/2023, 03/05/2024, and 05/20/2025. This notifies the market of intended Rule 144 sales procedures.
Actual sale timing, methods, and proceeds treatment are determined by holder actions and applicable Rule 144 conditions; subsequent filings may disclose transaction completion details.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Ironwood's (IRWD) Form 144 disclose?
Who is the issuer and trading venue shown on the Form 144 for IRWD?
AI-generated analysis. How Rhea-AI works. Not financial advice.